Search

Your search keyword '"Osama, Sabri"' showing total 18 results
Start Over Author "Osama, Sabri" Publisher © georg thieme verlag kg
18 results on '"Osama, Sabri"'

1. Cholinergic network modulation of food cue response in humans

Author

Michael Rullmann, Franziska Zientek, Swen Hesse, Julia Luthardt, PM Meyer, Osama Sabri, Georg-Alexander Becker, T Günnewig, J Neumann, M Patt, and E Schweickert de Palma

Subjects
Modulation, Cholinergic, Biology, Neuroscience, Food cue
Published
2020

2. 18 F-PI2620 Tau-PET for Assessment of Heterogeneous Neuropathology in Corticobasal Syndrome

Author

Alexander Drzezga, Victor L. Villemagne, Christian Haass, Catharina Prix, Osama Sabri, Robert Perneczky, G Höglinger, Mengmeng Song, Johannes Levin, Henryk Barthel, Matthias Brendel, T van Eimeren, A. Danek, Leonie Beyer, Mona Gehmeyr, Peter Bartenstein, Carla Palleis, Kai Bötzel, Andrew Stephens, and Julia Sauerbeck

Subjects
Pathology, medicine.medical_specialty, business.industry, medicine, Neuropathology, business
Published
2020

3. 18 F-PI2620 Tau-PET in Progressive Supranuclear Palsy – A Multi-Center Evaluation

Author

Marianne Patt, Jost-Julian Rumpf, John Seibyl, Mengmeng Song, Andreas Schildan, Sigrun Roeber, Michael Rullmann, Andrew W. Stephens, Jochen Hammes, Kenneth Marek, Leonie Beyer, Peter Bartenstein, Joseph Classen, Carla Palleis, Matthias Brendel, Jennifer Madonia, Matthias L. Schroeter, Alexander Drzezga, David Russell, Dorothee Saur, Thilo van Eimeren, Johannes Levin, Henryk Barthel, G. Hoeglinger, and Osama Sabri

Subjects
0301 basic medicine, Pathology, medicine.medical_specialty, business.industry, Standardized uptake value, Substantia nigra, medicine.disease, Statistical parametric mapping, eye diseases, Progressive supranuclear palsy, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Atrophy, Globus pallidus, Basal ganglia, medicine, Tauopathy, business, 030217 neurology & neurosurgery
Abstract

54 Background: Progressive supranuclear palsy (PSP) is a 4-repeat (4R) tauopathy and region-specific tau deposits establish the neuropathological diagnosis of “definite PSP” post mortem. Future interventional trials against tau in PSP would strongly benefit from biomarkers to validate the specific presence of the target and to monitor the target’s magnitude during therapy. First generation tau positron-emission-tomography (PET) ligands such as 18F-THK5351 or 18F-AV1451 were somewhat able to distinguish PSP patients from healthy controls (HC) or from patients with other neurodegenerative diseases, but relevant fractions of the PET signal in PSP may have been related to concomitant monoamine-oxidase (MAO) increases. The novel second generation tau-PET ligand 18F-PI2620 proved absent off-target binding to MAO and high affinity to 3/4R tau in Alzheimer’s disease (AD). The aim of this multicenter-evaluation was to investigate 18F-PI2620 in patients with suspected 4R tau pathology in clinically diagnosed PSP. Methods: Seventeen patients (70±7 y, n=8 female) with probable or possible PSP Richardson syndrome according to MDS-PSP criteria underwent 18F-PI2620 PET at four different centers together with ten HC and seven disease controls (Multi-system atrophy, Parkinson’s disease, and AD). PET scans were acquired 0-60 min p.i. followed by coregistration to a 18F-PI2620 template in the MNI space. Standardized uptake value ratios (SUVr) of predefined brain regions in the basal ganglia were generated using cerebellar scaling of a 30-60 min p.i. frame after inspection of the full dynamic range. SUVr data were compared between PSP, HC, and disease controls by an ANOVA including Bonferroni post hoc correction. Statistical parametric mapping (SPM, V12) was performed between PSP and HC (t-test). SUVr and SPM data were corrected for different centers. Additionally, disease severity measured by the PSP rating scale (PSPRS) was correlated with PET findings. An in vitro pilot autoradiography using 18F-PI2620 incubation of brain slices was performed for the globus pallidus of a single PSP patient and compared to the cortical binding in a specimen from an AD patient. Results: Our study indicates significantly elevated mean 18F-PI2620 SUVr in PSP patients (PSPRS: 40±17; range 13-71) in the globus pallidus (1.34±0.16; p = 0.001; d = 1.68) and the substantia nigra (1.33±0.14; p = 0.003; d = 1.49) when compared to HC (1.12±0.09 / 1.15±0.08). Disease controls showed a similar signal in the globus pallidus (1.11±0.06; p = n.s.) and a slight elevation in the substantia nigra (1.23±0.09; p = n.s.) when compared to HC. A voxel-wise analysis SPM revealed elevated 18F-PI2620 uptake in the globus pallidus, the substantia nigra as well as in the frontal and parietal cortex (all p 0.2). Subjects with low disease severity (PSPRS ≤ 30; n=4) already had a significantly elevated 18F-PI2620 uptake in the globus pallidus when compared to HC (1.38±0.13 vs. 1.12±0.09; p = 0.001; d = 2.32). Preliminary in vitro autoradiography showed distinguishable 18F-PI2620 binding in the globus pallidus of a PSP patient which was however far lower when compared to cortical binding in AD. Conclusions: The results of this preliminary multi-center evaluation indicate a value of 18F-PI2620 to diagnose and differentiate suspected PSP patients in vivo. The magnitude of tracer binding between patients seems to be variably expressed but not correlated with disease severity. These results indicate that 18F-PI2620 may show potential as a biomarker to assess tau pathology in PSP patients and that it may be helpful to establish earlier and more reliable diagnosis of PSP.

Published
2020

7. Binding characteristics of 18 F-PI-2620 differentiate the clinically predicted tau isoform in suspected 3/4-repeat and 4-repeat tauopathies

Author

Joseph Classen, Matthias Brendel, T van Eimeren, J Seibyl, Jochen Herms, Alexander Drzezga, Kenneth Marek, Osama Sabri, David S. Russell, Peter Bartenstein, Matthias L. Schroeter, Michael T. Barbe, Victor L. Villemagne, Leonie Beyer, G Höglinger, Andrew Stephens, Julia Sauerbeck, Johannes Levin, Henryk Barthel, and Mengmeng Song

Subjects
Gene isoform, Pi, Biology, Molecular biology
Published
2020

9. Association between Emotional Regulation (ER) and Prefrontal Noradrenalin Transporter (NAT) Availability in Human Obesity

Author

Julia Luthardt, Arne Dietrich, Osama Sabri, Anja Hilbert, Swen Hesse, Tatjana Schütz, M Patt, Anke McLeod, Georg-Alexander Becker, Franziska Zientek, and Michael Rullmann

Subjects
medicine.medical_specialty, Endocrinology, Nat, business.industry, Internal medicine, medicine, Emotional regulation, Transporter, business, Association (psychology), Human obesity
Published
2020

10. Perfusion-Phase 18 F-PI-2620 Tau-PET Imaging as a Surrogate Marker of Neuronal Injury

Author

Victor L. Villemagne, Mengmeng Song, G Höglinger, J Seibyl, Matthias L. Schroeter, David S. Russell, Alexander Nitschmann, Julia Sauerbeck, Marcus Unterrainer, Peter Bartenstein, Alexander Drzezga, Osama Sabri, Andrew Stephens, Jochen Herms, T van Eimeren, Johannes Levin, Henryk Barthel, Joseph Classen, Matthias Brendel, and Leonie Beyer

Subjects
Pathology, medicine.medical_specialty, Chemistry, Surrogate endpoint, Phase (waves), medicine, Pi, Perfusion
Published
2020

12. The interaction of lung cancer and adipose tissue in the development of cancer cachexia

Author

Claudia Hänel, Hubert Wirtz, Nicolas Linder, Johanna Pappisch, Armin Frille, J Meyer, Thomas Ebert, Osama Sabri, T Kerkhoff, Harald Busse, Hans-Jürgen Seyfarth, Michael Rullmann, Karen Steinhoff, Swen Hesse, and H. Kuhn

Subjects
business.industry, Cancer research, Adipose tissue, Medicine, Cancer cachexia, business, Lung cancer, medicine.disease
Published
2020

13. Effect of Pridopidine in Huntington Disease (HD) Patients and Healthy Volunteers (HVs) – A Simultaneous Sigma-1 Receptor PET/Multimodality MRI Study

Author

Michael Rullmann, Franziska Zientek, Igor D. Grachev, E Strauss, Michael R. Hayden, PM Meyer, M Patt, Bernhard Sattler, Andreas Kluge, Michal Geva, Marcus Bronzel, O Voges, Georg-Alexander Becker, Mark Forrest Gordon, JM Savola, Osama Sabri, Swen Hesse, Henryk Barthel, and Doug Marsteller

Subjects
Oncology, medicine.medical_specialty, chemistry.chemical_compound, Sigma-1 receptor, chemistry, business.industry, Internal medicine, Healthy volunteers, Medicine, Disease, business, Pridopidine
Published
2020

14. High sigma-1 receptor (S1R) and very low dopamine 2/dopamine 3 receptor (D2/D3R) occupancy at clinically relevant doses of pridopidine in healthy volunteers (HV) and Huntington disease patients (HD): a F-18-Fluspidine and F-18-Fallypride PET study

Author

L Rabinovich, Georg-Alexander Becker, O Voges, Swen Hesse, Michael R. Hayden, Juha-Matti Savola, M Patt, Franziska Zientek, Doug Marsteller, Mark Forrest Gordon, E Strauss, PM Meyer, Henryk Barthel, Igor D. Grachev, Marcus Bronzel, Bernhard Sattler, Michael Rullmann, Michal Geva, Osama Sabri, and Andreas Kluge

Subjects
Sigma-1 receptor, business.industry, Disease, Pharmacology, Pridopidine, chemistry.chemical_compound, chemistry, Fallypride, Dopamine, Healthy volunteers, medicine, Receptor, Fluspidine, business, medicine.drug
Published
2020

18. Pulmonary serotonin transporter availability in patients with COPD and pulmonary hypertension

Author

Hans-Jürgen Seyfarth, Hubert Wirtz, Michael Rullmann, Osama Sabri, M Patt, Georg-Alexander Becker, Julia Luthardt, Swen Hesse, and Armin Frille

Subjects
medicine.medical_specialty, COPD, biology, business.industry, Internal medicine, biology.protein, medicine, Cardiology, In patient, business, medicine.disease, Pulmonary hypertension, Serotonin transporter
Published
2020

Catalog

Books, media, physical & digital resources
See catalog results